CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
恶病质：接受 CAR-T 细胞治疗的 B 细胞非霍奇金淋巴瘤患者不良临床和功能结局的危险因素
英文原题：Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
查看英文原题
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
恶病质是一种肌肉消耗综合征，已知会影响多种癌症患者的临床病程，但尚未专门在接受CAR-T（CAR-T）细胞治疗的患者中进行研究。本研究在接受CAR-T 治疗的侵袭性B细胞非霍奇金淋巴瘤先导队列中，调查恶病质标志物与多种癌症及功能结局之间的关系。我们发现，预后营养指数与无进展生存期、总生存期和无残疾生存期相关；其他几项体重和血清恶病质标志物也与不良结局相关。这些数据提示，应在接受CAR-T 细胞治疗的人群中进一步研究恶病质标志物。
展开英文摘要原文
Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T.
We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.
论文信息
- 作者
- Roy I、Smilnak G、Burkart M、Hamilton E、Thorp K、Miyata S、Ma S、Pro B
- 第一作者单位
- Shirley Ryan AbilityLab, Chicago, Illinois, USA.United States
- 通讯作者单位
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.United States
- 期刊
- British journal of haematology2022 Apr
- 原文标识
- PubMed 35141891 · DOI 10.1111/bjh.18054